Search results for "carcinoid syndrome"

showing 5 items of 5 documents

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germa…

2021

Abstract Background The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors. Objective To evaluate the long-term treatment response in patients with neuroendocrine tumors receiving lanreotide autogel in routine clinical practice. Methods Non-interventional, 24-month study in patients with neuroendocrine tumors treated with lanreotide autogel (NCT01840449). Results Patients (n=80) from 26 centers in Germany and Austria were enrolled. Neuroendocrine tumors were mainly grade 1/2, metastasized, intestinal, and associated with carcinoid syndrome; 88.9% had received previous neuroendocrine tumor treatment. Of those, 84.4% had pre…

MaleOncologymedicine.medical_specialtyEndocrinology Diabetes and Metabolismchromogranin AMedizindiarrheacarcinoid syndromeOctreotideAntineoplastic Agents030209 endocrinology & metabolismNeuroendocrine tumorsPeptides CyclicArticleflushing03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeGermanyInternal medicineOutcome Assessment Health CareInternal MedicinemedicineClinical endpointHumansAgedMalignant Carcinoid Syndromebiologybusiness.industryChromogranin AGeneral MedicineMiddle Agedmedicine.diseaseNeuroendocrine Tumorsquality of lifeTolerabilityAustria030220 oncology & carcinogenesisbiology.proteinFemaleObservational studySomatostatinbusinessCarcinoid syndromemedicine.drugExperimental and Clinical Endocrinology & Diabetes
researchProduct

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available s…

2015

Edward M Wolin,1 Barbara Jarzab,2 Barbro Eriksson,3 Thomas Walter,4 Christos Toumpanakis,5 Michael A Morse,6 Paola Tomassetti,7 Matthias M Weber,8 David R Fogelman,9 John Ramage,10 Donald Poon,11 Brian Gadbaw,12 Jiang Li,12 Janice L Pasieka,13 Abakar Mahamat,14 Fredrik Swahn,15 John Newell-Price,16 Wasat Mansoor,17 Kjell Öberg3 1Markey Cancer Center, University of Kentucky, Lexington, KY, USA; 2Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland; 3Department of Medical Sciences, Endocrine Oncology Unit, University Hospital, Uppsala, Sweden; 4Department of Medical Oncology, Ed…

MaleTime FactorsPharmaceutical ScienceOctreotideKaplan-Meier EstimateNeuroendocrine tumorsDigestive System NeoplasmsOctreotideGastroenterologychemistry.chemical_compoundDrug DiscoveryOdds RatioOriginal ResearchAged 80 and oversomatostatin analoguesDrug SubstitutionHazard ratioMiddle AgedTumor BurdenTreatment OutcomeFemalemedicine.symptomSomatostatinCarcinoid syndromemedicine.drugAdultmedicine.medical_specialtyNauseaCarcinoid tumorscarcinoid syndromeAntineoplastic AgentsCarcinoid TumorDisease-Free SurvivalDouble-Blind MethodInternal medicinemedicineHumansProgression-free survivalAgedProportional Hazards ModelsPharmacologypasireotideCancer och onkologiDrug Design Development and Therapybusiness.industrylcsh:RM1-950medicine.diseasesymptom controlPasireotidelcsh:Therapeutics. PharmacologyEndocrinologyLogistic ModelschemistryDrug Resistance NeoplasmDelayed-Action PreparationsCancer and Oncologyneuroendocrine tumorsbusinessprogression-free survival
researchProduct

Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal.

2020

Neuroendocrine tumors (NETs) frequently overexpress somatostatin receptors (SSTR) on their cell surface. The first-line pharmacological treatment for inoperable metastatic functioning well-differentiated NETs are somatostatin analogs. On second line, Lu-DOTA-TATE (177Lu-DOTA0 Tyr 3 octreotate) has shown stabilization of the disease and an increase in progression free survival, as well as effectiveness in controlling symptoms and increasing quality of life. The management of functional NETs before and during LU-DOTA-TATE treatment is specially challenging, as several complications such as severe carcinoid and catecholamine crisis have been described. The aim of this review is to establish pr…

Oncologymedicine.medical_specialtycatecholaminergic crisisMEDLINElcsh:Medicinecarcinoid syndrome030209 endocrinology & metabolismReviewNeuroendocrine tumors03 medical and health scienceschemistry.chemical_compound0302 clinical medicinesystematic reviewInternal medicinemedicinecarcinoid crisisProgression-free survivalDOTA-TATEpeptide receptor radionuclide therapyhormonal crisisOctreotatebusiness.industrySomatostatin receptorlcsh:RGeneral Medicinemedicine.diseaseSystematic reviewchemistry030220 oncology & carcinogenesisneuroendocrine tumorsbusiness177Lu-DOTA-TATECarcinoid syndromeJournal of clinical medicine
researchProduct

Safety of high doses of somatostatin analogs in well differentiated NENs in elderly

2019

Abstract Background Neuroendocrine neoplasms (NENs) are a group of heterogeneous neoplasms which can be treated with different therapies: in well differentiated (WD) NENs analogs of somatostatin (SSA) can be used considering their proved antineoplastic and antisecretory effects. This is a multicenter study to investigate the safety of high doses (HDD) analogs of somatostatin (SSA) in WD NENs with particular attention for patients over 70 years of age. Methods We collected clinical data from 13 Italian NENs dedicated Units. Patients with WD NENs, in progression on previous treatments, included SSA, and subsequently treated with HDD-SSA, were considered. Results 170 pts were included: 61.76% …

medicine.medical_specialtyGastrinomabusiness.industryHematologyNeuroendocrine tumorsmedicine.diseaseGastroenterologyZollinger-Ellison syndromeSteatorrheaOncologyInternal medicineCholecystitisMedicinemedicine.symptombusinessInsulinomaCarcinoid syndromeMalignant Carcinoid SyndromeAnnals of Oncology
researchProduct

Duodenal perforation as presentation of gastric neuroendocrine tumour: A case report

2020

Highlights • Gastric neuroendocrine neoplasms (g-NENs) represent the most frequent digestive NENs and are increasingly recognized thanks to diffusion of upper gastrointestinal endoscopy. • g-NENs can be sporadic or associated with multiple endocrine neoplasia type 1 (MEN-1) and present with a functional Zollinger-Ellison syndrome. • We described a case of a 60 years old Caucasian male came to emergency room with diffuse abdominal pain and leukocytosis on blood tests. • At the level of the pyloric portion we found irregularly thickened walls associated with a small fluid collection and bubbles of free air. On exploratory laparoscopy we found a large perforation (about 5 cm of size) in the fi…

medicine.medical_specialtyPerforation (oil well)Case ReportNeuroendocrine tumorsAsymptomaticGastroenterologyExploratory laparoscopyGastric perforation03 medical and health sciences0302 clinical medicineInternal medicinemedicineMultiple endocrine neoplasiaDuodenal PerforationGastrinomabusiness.industrymedicine.diseasedigestive system diseasesZollinger-Ellison syndrome030220 oncology & carcinogenesisGastric NETEmergency surgery030211 gastroenterology & hepatologySurgerymedicine.symptombusinessCarcinoid syndrome
researchProduct